{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:03:20Z","timestamp":1785247400525,"version":"3.55.0"},"reference-count":20,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"DOI":"10.5005\/jp-journals-10018-1502","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:10:11Z","timestamp":1785244211000},"page":"112-118","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management"],"prefix":"10.5005","volume":"16","author":[{"given":"Rowan","family":"Bandaranaike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Rutland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Rutland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref=1","unstructured":"1. Fink J. About 6% of U.S. adults say they currently take a GLP-1 medication [Internet]. Gallup; 2024 [cited 2026 Jan 15]. Available from: https:\/\/news.gallup.com\/poll\/648680\/adults-say-currently-take-glp-medication.aspx."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"2. Drucker DJ. The GLP-1 journey: From discovery science to therapeutic impact. J Clin Invest 2024;134(2):e175634. DOI: 10.1172\/JCI175634.","DOI":"10.1172\/JCI175634"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387(3):205\u2013216. DOI: 10.1056\/NEJMoa2206038.","DOI":"10.1056\/NEJMoa2206038"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"4. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391(2):109\u2013121. DOI: 10.1056\/NEJMoa2403347.","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"5. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab 2021;46:101102. DOI: 10.1016\/j.molmet.2020.101102.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"6. Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol 2024;22(4):705\u2013707. DOI: 10.1016\/j.cgh.2023.11.002.","DOI":"10.1016\/j.cgh.2023.11.002"},{"key":"ref=7","unstructured":"7. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists [Internet]. ASA 2023. Available from: https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. [Last accessed on: 15 January 2026]."},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"8. Kobori T, Onishi Y, Yoshida Y, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. JAMA Netw Open 2023;6(10): e2329554.","DOI":"10.1111\/jdi.14005"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"9. Colwill M, Povlsen S, Pollok R, et al. Glucagon-like peptide (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential. J Crohns Colitis 19(9):jjaf167. DOI: 10.1093\/ecco-jcc\/jjaf167.","DOI":"10.1093\/ecco-jcc\/jjaf167"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"10. Ahmad AI, Garg S, Jacobs J, et al. Holding vs continuing GLP-1\/GIP agonists before upper endoscopy: The OCULUS randomized clinical trial. JAMA Intern Med 2026. DOI: 10.1001\/jamainternmed.2026. 0027.","DOI":"10.1001\/jamainternmed.2026.0027"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"11. American Diabetes Association Professional Practice Committee. Diabetes care in the hospital: Standards of care in diabetes\u20142026. Diabetes Care 2026;49(Suppl 1):S339\u2013S355.","DOI":"10.2337\/dc26-S016"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"12. Hocking SL, Scott DA, Remedios ML, et al. 2025 ADS\/ANZCA\/GESA\/NACOS clinical practice recommendations on the peri-procedural use of GLP-1\/GIP receptor agonists. Anaesth Intensive Care 2025;53(5):300\u2013306. DOI: 10.1177\/0310057X251355288.","DOI":"10.1177\/0310057X251355288"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"13. Facciorusso A, Giannini EG, Tacelli M, et al. Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: A position paper by the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2026. DOI: 10.1016\/j.dld.2026.02.018.","DOI":"10.1016\/j.dld.2026.02.018"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"14. Abdulraheem A, Abujaber B, Ayers L, et al. Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: An updated systematic review and meta-analysis. Surg Endosc 2025:39:5135\u20135151. DOI: 10.1007\/s00464-025-11962-4.","DOI":"10.1007\/s00464-025-11962-4"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"15. Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: A systematic review and meta-analysis. Gastrointest Endosc 2025;101(4):762\u2013771. DOI: 10.1016\/j.gie.2024.12.019.","DOI":"10.1016\/j.gie.2024.12.019"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"16. Facciorusso A, Ramai D, Dhar J, et al. Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: A meta-analysis. Clin Gastroenterol Hepatol 2025;23(4):715\u2013725. DOI: 10.1016\/j.cgh.2024.07.021.","DOI":"10.1016\/j.cgh.2024.07.021"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"17. Tan Y, Zhang X, Lv XH, et al. Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis. Dig Liver Dis 2025;57(6):1377\u20131385. DOI: 10.1016\/j.dld.2025.03.002.","DOI":"10.1016\/j.dld.2025.03.002"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"18. Hiramoto B, McCarty TR, Lodhia NA, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: A systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol 2024;119(6):1126\u20131140. DOI: 10.14309\/ajg.0000000000002820.","DOI":"10.14309\/ajg.0000000000002820"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"19. Kruisselbrink R, Gharapetian A, Chaparro LE, et al. Diagnostic accuracy of point-of-care gastric ultrasound. Anesth Analg 2019;128(1):89\u201395. DOI: 10.1213\/ANE.0000000000003372.","DOI":"10.1213\/ANE.0000000000003372"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"20. Crespo J, Rodr\u00edguez-Duque JC, Iruzubieta P, et al. GLP-1 receptor agonists and gastrointestinal endoscopy: A narrative review of risks, management strategies, and the need for clinical consensus. J Clin Med 2025;14(16):5597. DOI: 10.3390\/jcm14155597.","DOI":"10.3390\/jcm14155597"}],"container-title":["Euroasian journal of hepato-gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ejohg.com\/doi\/pdf\/10.5005\/jp-journals-10018-1502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:10:21Z","timestamp":1785244221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejohg.com\/doi\/10.5005\/jp-journals-10018-1502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["10.5005\/jp-journals-10018-1502"],"URL":"https:\/\/doi.org\/10.5005\/jp-journals-10018-1502","relation":{},"ISSN":["2231-5047","2231-5128"],"issn-type":[{"value":"2231-5047","type":"print"},{"value":"2231-5128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}